Hot Investor Mandate: Pharmaceutical Company Seeks Early Stage Therapeutic Partnerships in Cardiovascular, Metabolic Disease, Rare Diseases, and More

4 Apr

A publicly traded pharmaceutical company based in Western Europe is interested in licensing and M&A opportunities in its core therapeutic areas of urology, cardiovascular, gastrointestinal and metabolic diseases, and also in all rare disease/orphan drug assets. The firm will consider partnerships worldwide. Particularly in the rare disease space, the firm prefers to invest in global rights.

The firm is interested in early stage therapeutic partnerships in rare diseases, including in preclinical assets provided that there is strong preclinical proof of concept data for the asset (such as strong efficacy data from an animal model that are relevant and reflective of the human condition). The firm generally does not invest in rare oncology assets but is otherwise open to a wide range of rare disease opportunities. In other core areas (urology, cardiovascular, gastrointestinal, and central nervous system) the firm prefers to partner with companies that have obtained solid human proof of concept data. The firm can be a hands-on development and manufacturing partner in small molecule therapeutics, but not in biologics or cell therapies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: